SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer

Status Not yet recruiting

Clinical Trial Summary

A phase Ib/II clinical study on the safety, pharmacokinetic characteristics, and preliminary efficacy of SC0191 combination chemotherapy in patients with advanced ovarian cancer.

Clinical Trial Description

The phase 1b/2,multicenter, open-label study, contains 2 parts. Part 1 Dose Escalation of SC0191 combination chemotherapy: Part 1 will estimate the RP2D in dose escalation cohorts in patients withadvanced ovarian cancer. Part 2 Dose Expansion of SC0191 plus Chemotherapy. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06055348
Study type	Interventional
Source	Biocity Biopharmaceutics Co., Ltd.
Contact	Xiaohua Wu
Phone	021-64175590
Email	wu.xh@fudan.edu.cn
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	October 30, 2023
Completion date	November 30, 2025

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT03611179` - Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer	Phase 2
Completed	`NCT04135521` - Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian Cancer
Completed	`NCT01462149` - Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer	Phase 2
Terminated	`NCT03292172` - A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer	Phase 1
Not yet recruiting	`NCT05794659` - Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer	Phase 2
Completed	`NCT04360629` - Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer	N/A
Active, not recruiting	`NCT00516724` - Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel	Phase 1
Completed	`NCT03158935` - The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial	Phase 1
Completed	`NCT05775549` - A Study to Characterize the Outcomes of Olaparib Maintenance Monotherapy in Newly Diagnosed BRCAwt Ovarian Cancer
Active, not recruiting	`NCT03737643` - Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients	Phase 3
Completed	`NCT01290471` - Study to Assess the Safety and Tolerability of U3-1565 in Subjects With Advanced Solid Malignant Tumors	Phase 1
Recruiting	`NCT04862325` - SOPHIE Trial: Surgery in Ovarian Cancer With PreHabilitation In ERAS	N/A
Completed	`NCT01989546` - Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations	Phase 1/Phase 2
Recruiting	`NCT04556539` - Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer	Phase 2
Completed	`NCT03161132` - Resistant Ovarian Cancer, Olaparib and Liposomal Doxorubicin	Phase 2
Active, not recruiting	`NCT04065009` - The IPLA-OVCA Trial, Intra-Peritoneal Local Anaesthetics in Ovarian Cancer	Phase 3
Active, not recruiting	`NCT01844986` - Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.	Phase 3
Not yet recruiting	`NCT05924776` - Plasmodium Immunotherapy for Advanced Ovarian Cancer	Phase 2/Phase 3
Recruiting	`NCT03878849` - Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®	Phase 2